1. Introduction {#s0005}
===============

The extent of myocardial tissue loss, as assessed by infarct size, is a key determinant of the prognosis of patients with acute myocardial infarction ([@bb0070], [@bb0075]). Hence, limiting the infarct size is of paramount importance to ameliorate subsequent morbidity and mortality in affected patients ([@bb0155], [@bb0220], [@bb0115], [@bb0120], [@bb0055]). Given the magnitude of the problem (\> 900,000 acute myocardial infarctions per year in the United States ([@bb0170]), the implications of developing effective cardioprotective therapies are immense, both from the perspective of public health and the financial burden of health care. Though reperfusion therapy using thrombolytic agents has become the mainstay for treatment of patients with myocardial infarction, the benefits of this therapy have been shown to be reduced by factors such as severity of ischemia, inadequate reflow, presence of residual stenosis, coronary reocclusion, and reperfusion injury ([@bb0210], [@bb0215]). The biochemical, ionic, and signal transduction changes that occur within cardiomyocytes subjected to ischemia are exacerbated by reperfusion. Elucidation of the precise mechanisms mediating myocardial ischemia/reperfusion (I/R) injury is vital to accelerate the discovery of new and powerful adjunctive therapies to enhance the net benefit of reperfusion.

The signaling pathways involved in the response to myocardial I/R injury are complex. Intracellular signal transducers such as the Rho GTPases have been shown to modulate the response to I/R injury in mice ([@bb0200], [@bb0230], [@bb0255]). Formins modulate Rho-GTPase signal transduction mechanisms ([@bb0130]) and regulate actin polymerization ([@bb0175]). The mammalian Diaphanous-related formin 1 (DIAPH1; also known as mDia1) is a canonical effector for Rho small GTP-binding proteins. When activated by GTP-bound RhoA, DIAPH1 relies upon its formin homology-2 domain to elongate linear actin filaments by adding actin monomers to their barbed ends ([@bb0175]). DIAPH1 also signals to the nucleus via the myocardin-related transcription factor/serum response factor (SRF) axis to effect gene expression ([@bb0110]). DIAPH1 interacts with the cytoplasmic domain of the receptor for advanced glycation end-products (RAGE) through its poly-proline-rich formin homology-1 domain. In response to RAGE ligand stimulation, DIAPH1 participates in signal transduction in smooth muscle cells ([@bb0235]), macrophages ([@bb0260], [@bb0040]), immune cells ([@bb0195]), and transformed cells ([@bb0080]). While RAGE is known to be an essential component of the *in vivo* cardiac response to I/R, knowledge of the role of DIAPH1 in such a response is unexplored.

To fill this knowledge gap, we subjected global *Diaph1* knockout (*Diaph1*^--/--^) mice, deficient in DIAPH1 protein expression, and their wild-type (WT) littermates to I/R injury. We demonstrate that DIAPH1 expression was induced by I/R in murine hearts and mediated I/R injury through an F:G actin-regulated transcriptional mechanism that modulated calcium transporters, thereby leading to functional derangement in the I/R heart.

2. Materials and Methods {#s0010}
========================

2.1. Animal Studies {#s0015}
-------------------

All procedures were approved by the Institutional Animal Care and Use Committee of New York University Langone Medical Center (NYULMC) and conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH) (8th Edition, 2011, ISBN 10: 0-309-15400-6). The Animal Care and Use Program at NYULMC is in full compliance with NIH policy (NYULMC Compliance Number is A3435-01).

Homozygous *Diaph1*^--/--^ mice were generated at the Van Andel Institute and obtained from Dr. Arthur Alberts ([@bb0145]). The mice were backcrossed 14 generations into C57BL/6J prior to any experimentation. Non-transgenic WT littermates were used as controls for *in vivo* and *ex vivo* I/R studies, as described below. Mouse studies were performed using male WT and *Diaph1*^--/--^ mice aged 4--6 months as specified.

2.2. In Vivo I/R {#s0020}
----------------

Male mice aged approximately 4-6 months were anesthetized with an intraperitoneal injection of ketamine and xylazine (120 mg/kg body weight and 5 mg/kg body weight, respectively) and subjected to left anterior descending coronary artery occlusion followed by reperfusion (LAD/reperfusion) as previously described ([@bb0005]). The surgical procedures were performed by an operator naive to the mouse genotype. Briefly, the LAD was ligated for 30 min and then blood flow was restored. Sham animals were subjected to the surgical procedure without LAD occlusion. After 48 h, mice were anesthetized with isoflurane (4% to induce and 1.5--2% to maintain anesthesia, inhaled via a nose cone) for the duration of the procedure and 2-dimensional echocardiography was performed on a Vevo 2100 System (Visual Sonics, Toronto, Ontario, Canada). Echocardiographic images were analyzed by a researcher naive to the genotype. The left ventricular end-diastolic and end-systolic dimensions were measured and percent fractional shortening was calculated. Mice were then anesthetized with an intraperitoneal injection of ketamine and xylazine (100 mg/kg body weight and 10 mg/kg body weight, respectively) and the hearts were excised. A subset of hearts was used to assess area at risk and infarct area by 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) and Evan\'s blue staining. The remainders of the hearts were collected for biochemical analysis.

2.3. Ex Vivo I/R {#s0025}
----------------

Mice were anesthetized with an intraperitoneal injection of ketamine and xylazine (100 mg/kg body weight and 10 mg/kg body weight, respectively) and then hearts were isolated from WT and *Diaph1*^--/--^ mice aged 4 months and perfused with Krebs-Henseleit buffer containing (in mM) the following: 118 NaCl, 4.7 KCl, 2.5 CaCl~2~, 1.2 MgCl~2~, 25 NaHCO~3~, 5 glucose, 0.4 palmitate, 0.4 BSA, and 70 mU/l insulin, as previously described ([@bb0085]). Left ventricular developed pressure (LVDP), left ventricular end diastolic pressure (LVEDP) and coronary perfusion pressure (PP) was continuously monitored using pressure transducer (ADInstruments). After an equilibration period of 30 min, global ischemia was performed for 30 min in the hearts, followed by 60 min of reperfusion (global I/R).

2.4. Cell Studies {#s0030}
-----------------

Rat H9C2 cardiomyoblasts (ATCC, Manassas, VA) were cultured to assess the effects of *in vitro* I/R injury. Short-hairpin RNA (shRNA) particles (Sigma-Aldrich, St. Louis, MO) were used to silence *Diaph1* (sh*Diaph1*) according to the manufacturer's instructions. Control H9C2 cells underwent the same protocol using control shRNA particles with a scrambled sequence (shScr). For subsequent experiments, shScr and sh*Diaph1* cells were placed in a hypoxia chamber (Biospherix, Lacona, NY) for 30 min of hypoxia (0.5% oxygen, 5% CO~2~) at 37 °C followed by 60 min of reoxygenation in 5% CO~2~ incubator (hypoxia/reoxygenation, H/R). Control cells were kept in a standard cell culture incubator (37 °C, 5% CO~2~) to simulate normoxia. All cell studies (including the hypoxia-reoxygenation studies) used DMEM supplemented with 10% FBS and 1 % penicillin-streptomycin. Cells were collected at the end of reoxygenation in ice cold PBS for further biochemical analysis. Lactate dehydrogenase (LDH) release into the media was measured to assess cardiomyocyte injury using a commercially available kit (Pointe Scientific, Canton, MI). The cells were treated with 100 nmol/l jasplakinolide, 1 μmol/l latrunculin B, or DMSO vehicle (Sigma-Aldrich) for 1 h prior to hypoxia when specified. Early growth response 1 (EGR1) was overexpressed in shScr and sh*Diaph1* cells using an adenoviral vector (Vector Biolabs, Malvern, PA). We subjected human AC16 cardiomyocytes ([@bb0050]) (obtained as a gift from Dr. Mercy Davidson at Columbia University, New York, NY) to H/R when noted.

Primary cardiomyocytes were isolated from SHAM or LAD/reperfused adult mice hearts by a modified method as published by us and others ([@bb0045], [@bb0190]). In brief, hearts excised from anesthetized mice were subjected to Langendorff perfusion with Krebs medium containing calcium (2.5 mM) for 5 min, followed by perfusion with Calcium free Krebs medium (8--10 min). Hearts were then perfused with an enzymatic solution containing collagenase type II (0.35 mg/ml; Worthington, Freehold, NJ) and protease type XIV (0.01 mg/ml, Sigma) for 5--8 min. 50 μM Ca^2 +^ was then added into the enzyme solution for perfusing the heart for another 5--10 min until the hearts became soft. The hearts were then removed, minced into small pieces and subjected to further serial enzymatic digestion at 37° C for \~ 3 min. Cardiomyocytes in the digests were collected by centrifugation at 500 rpm and the myocyte pellet was resuspended in storage medium (Ca^2 +^ free Kreb\'s containing 1% BSA and Calcium (125 μM). Extracellular Ca^2 +^ was incrementally added back to 500 μM over a period of 40 min. The rod shaped myocytes settled down immediately, whereas round ones and other cells were floating in the supernatant. By aspirating the supernatant and repeated washing, a rod-shaped myocyte population was obtained. Cardiomyocytes were incubated in Kreb\'s buffer containing 1 mM Ca^2 +^ for the following study. Cell viability was assessed by using the commercially available CellTiter-FluorTM kit (Promega, Madison, WI, USA). Characterization of cardiomyocytes was done by staining with α-sarcomeric actinin antibody (Sigma, St. Louis, MO, USA) and FACS study.

2.5. Biochemical Analyses {#s0035}
-------------------------

Extracts from mouse hearts, H9C2 cells, and AC16 cells were obtained by homogenization in cell lysis buffer (Cell Signaling, Danvers, MA). Nuclear fractions were prepared using a commercially available kit (Thermo Scientific, Rockford, IL). Protein concentrations were determined using a DC Protein Assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein were separated by SDS-PAGE and proteins were transferred to a nitrocellulose membrane (Life Technologies, Carlsbad, CA), which was probed with primary antibodies according to the manufacturer\'s instructions. We used primary antibodies (1:1000) as follows: mDia1 (DIAPH1), β-actin, ROCK2, nucleoporin p62 (BD Biosciences, San Jose, CA), pan-actin (Cytoskeleton, Denver, CO), GAPDH (Genetex, Irvine, CA), EGR1, SERCA2a (Santa Cruz, Dallas, TX), DIAPH1, myocardin, NCX1, calsequestrin, DIAPH2, histone 3, GAPDH (AbCam, Cambridge, UK), phosphorylated (ser16) and total phospholamban (EMD Millipore, Billerica, MA), GAPDH (Genetex, Irvine, CA), phosphorylated and total Rac1, RhoA, phosphorylated (ser9) and total GSK3β (Cell Signaling, Danvers, MA). We visualized and quantitated blots with a fluorescent western blot detection system (Licor, Lincoln, NE).

We measured the ratio of filamentous to globular (F:G) actin using a kit according to the manufacturer (Cytoskeleton, Denver, CO). Briefly, cell or tissue extracts were homogenized in F actin stabilization buffer, centrifuged to separate F and G actin, and then probed using Western blotting with a pan-actin antibody. In addition, we also used complimentary phalloidin/DNase I Staining method to determine F:G changes in H9C2 cells. Briefly, sub-confluent shScr and shDiaph1 H9C2 cells grown on gelatin-coated coverslips were placed in a hypoxia chamber (Biospherix, Lacona, NY) for either normoxia or 30 min of hypoxia (0.5% oxygen, 5% CO~2~) at 37° C followed by 60 min of reoxygenation (H/R). After these treatments, cells were washed with ice-cold PBS fixed in formaldehyde, permeabilized and stained in Alexa Fluor 647 Phalloidin and Deoxyribonuclease I Alexa Fluor 594 (Molecular Probes). Confocal microscopy was performed on a Zeiss LSM 510 Confocal Microscope, Single field images of 1024 × 1024 pixels were collected to visualise F-actin labelled with Alexa Fluor 647 Phalloidin and G-actin labelled with Alexa Fluor® 594 DNase I.

RNA was isolated from H9C2 cells using a commercially available kit (Qiagen, Valencia, CA) followed by reverse transcription (Bio-Rad) and RT-PCR using rat primers for *Srf*, *Tagln* (gene for Sm22), and *Fos* (the gene for c-Fos), with all values normalized to *Ppia* (Life Technologies).

2.6. Chromatin Immunoprecipitation (ChIP) {#s0040}
-----------------------------------------

ChIP was performed using the ChIP-IT kit (Active Motif, Carlsbad, CA). Briefly, mouse hearts subjected to LAD/reperfusion were crosslinked with formaldehyde in PBS for 15 min at room temperature and were processed as per instructions provided by the manufacturer to obtain chromatin. The chromatin was initially pre-cleared using protein-G beads and subsequently treated with SRF antibody (Abcam, Cambridge, UK) at a concentration of 1:200 for immunoprecipitation overnight. The immunoprecipitated ChIP product was washed, reverse crosslinked, treated with proteinase K, and eluted to obtain the ChIP enriched DNA. Simultaneously, IgG was used as a negative control to check the efficiency of the ChIP experiment. Wild Type heart lysates were incubated with negative control IgG for ChIP pulldown. 25 ng of ChIP enriched DNA was used to perform PCR for *Egr1*, *Atp2a2*, and *Slc8a1*. The PCR products were run on a 2% agarose gel and the amplicons were visualized using UV light.

2.7. Statistics {#s0045}
---------------

All values are presented as the mean ± standard error of the mean. Data were analyzed by unpaired two-tailed *t*-tests, and one-way or two-way ANOVAs to assess the difference between groups as specified. A probability value of ≤ 0.05 was considered significant.

3. Results {#s0050}
==========

3.1. I/R Injury Increases DIAPH1 Expression {#s0055}
-------------------------------------------

To evaluate the effects of I/R on DIAPH1 expression, we subjected male WT mice, aged 4-6 months, to left anterior descending coronary artery (LAD) occlusion for 30 min, followed by 48 h of reperfusion (LAD/reperfusion) or to sham surgery, and we measured DIAPH1 expression in whole cardiac tissue by immunoblotting using DIAPH1-specific antibodies. LAD/reperfused mouse hearts displayed a significant increase in DIAPH1 protein expression relative to sham controls ([Fig. 1](#f0005){ref-type="fig"}a). Thirty minutes of LAD occlusion followed by either 6, 24 or 48 h of reperfusion resulted in significant increases in DIAPH1 expression in mouse hearts compared with sham treatment, as assessed by Western blot analysis (*P \<* 0.05; [Fig. 1](#f0005){ref-type="fig"}b). Cardiomyocytes isolated from WT mouse hearts after 48 h of reperfusion exhibited significant increases in *Diaph1* gene expression compared to cardiomyocytes isolated from sham treated hearts ([Fig. 1](#f0005){ref-type="fig"}c.). To confirm these results *in vitro*, H9C2 rat cardiomyoblasts ([Fig. 1](#f0005){ref-type="fig"}d) and AC16 human cardiomyocytes (Supplementary Fig S1) were subjected to 30 min of hypoxia followed by 60 min of reoxygenation (hypoxia/reoxygenation, H/R), and both displayed elevated levels of DIAPH1 relative to cells maintained at normal oxygen levels.Fig. 1I/R injury increased DIAPH1 protein levels. (a) Hearts from wild-type (WT) C57BL/6 mice were retrieved, and lysates were subjected to Western blot analysis for the detection of DIAPH1 epitopes in mice subject to sham procedure (48 h) or at 48 h of reperfusion. After probing with the primary antibody, blots were reprobed with anti-GAPDH IgG. Relative density units are reported; n = 5 mice/group. (a) DIAPH1/GAPDH expression is increased in WT mouse hearts after LAD/reperfusion (n = 8/group; \*p \< 0.05 vs. sham). (b) To probe for DIAPH1 changes at various time points during reperfusion, hearts were retrieved at 6 or 24, or 48 h after reperfusion or 48 h after sham procedure (identical anesthesia and surgery but without LAD occlusion) and lysates were subjected to Western blot analysis as in 1a. (n = 4/group; \*p \< 0.05 vs. sham). (c) mRNA expression of *Diaph1* was increased in cardiomyocytes isolated from hearts after 48 h of recovery (n = 5/group; \*p \< 0.05 vs sham), (d) DIAPH1/GAPDH expression is increased in H9C2 cells after H/R (n = 5--8/group; \*p \< 0.05 vs. normoxia). Unpaired two-tailed *t*-tests were used; a p-value \< 0.05 was considered significant.Fig. 1

3.2. Diaph1 Deletion Reduces Infarct Size and Damage After I/R {#s0060}
--------------------------------------------------------------

To determine potential roles for DIAPH1 in the heart after I/R-mediated injury, we subjected *Diaph1*^--/--^ and WT mice to LAD/reperfusion. Infarct size was significantly lower in *Diaph1*^--/--^ mice than in WT at 48 h, without differences in area at risk ([Fig. 2](#f0010){ref-type="fig"}a--b). At 48 h, *Diaph1* deletion resulted in a significantly higher fractional shortening ([Fig. 2](#f0010){ref-type="fig"}c) and ejection fraction ([Fig. 2](#f0010){ref-type="fig"}d), as measured by echocardiography (Supplementary Fig S2), relative to WT mice after LAD/reperfusion ([Fig. 2](#f0010){ref-type="fig"}c). Other cardiac functional measures such as stroke volume were also improved in *Diaph1*^--/--^ hearts ([Table 1](#t0005){ref-type="table"}). At baseline, prior to LAD ligation, cardiac functional measures were similar in WT and *Diaph1*^--/--^ hearts ([Table 1](#t0005){ref-type="table"}). Isolated perfused *Diaph1*^--/--^ mouse hearts subjected to global ischemia followed by reperfusion (*ex vivo* I/R) displayed significantly improved recovery of left ventricular developed pressure during reperfusion, relative to WT hearts ([Fig. 2](#f0010){ref-type="fig"}e). Left ventricular end diastolic pressure was attenuated in *Diaph1*^--/--^ mouse hearts after *ex vivo* I/R compared to WT hearts ([Table 2](#t0010){ref-type="table"}). In cultured H9C2 cells, the release of lactate dehydrogenase (LDH; a marker of injury induced by H/R), was significantly attenuated in short-hairpin (sh)*Diaph1*-silenced cells relative to control shRNA cells (shScr; [Fig. 2](#f0010){ref-type="fig"}f). These results demonstrate that genetic deletion of *Diaph1* protects hearts from pathological and functional indices of I/R injury.Fig. 2*Diaph1* deletion reduced myocardial I/R injury. (a) *Diaph1* deletion decreased infarct area (% of area at risk) in mouse hearts after LAD/reperfusion vs. WT (n = 10/group; \*p \< 0.05 vs. WT LAD) while (b) maintaining area at risk. (c) *Diaph1* deletion improved fractional shortening after LAD/reperfusion (n = 10/group; \*p \< 0.05 vs. WT LAD). (d) *Diaph1* deletion improved ejection fraction after LAD/reperfusion (n = 10/group; \*p \< 0.05 vs. WT LAD) (e) Left ventricular developed pressure (LVDP) recovery was improved in hearts isolated from *Diaph1*^--/--^ mice compared to WT after *ex vivo* I/R (n = 6/group; \*p \< 0.05 vs. WT I/R). (f) LDH release was reduced in sh*Diaph1* cells after H/R compared to shScr (n = 15--16/group; \*p \< 0.05 vs. shScr H/R). Unpaired two-tailed *t*-tests were used; a p-value \< 0.05 was considered significant.Fig. 2Table 1Echocardiography measurements of cardiac function in *LAD/reperfused* hearts.Table 1ParameterWT*Diaph1*^*-/-*^*P* value**Pre LAD/reperfusion** Heart rate (beats/min)556 ± 63532 ± 46NS LV ESD (mm)1.81 ± 0.11.78 ± 0.2NS LV EDD (mm)2.8 ± 0.22.9 ± 0.3NS LV mass (mg)98 ± 14116 ± 18NS Cardiac output (ml/min)10.6 ± 2.111. ± 1.9NS Stroke volume (ml/min)19.8 ± 2.224.5 ± 3.6NS LV thickness at end systole (mm)1.44 ± .321.54 ± 0.36NS**Post LAD/reperfusion (48 h after reperfusion)** Heart rate (beats/min)496 ± 28502 ± 35NS LV ESD (mm)3.6 ± 0.42.2 ± 0.3\< 0.05 LV EDD (mm)4.1 ± 0.53.3 ± 0.2\< 0.05 LV mass (mg)112 ± 19121 ± 22NS Cardiac output (ml/min)12.6 ± 1.517.8 ± 2.6\< 0.05 Stroke volume (ml/min)21.3 ± 4.836.4 ± 2.9\< 0.05 LV wall thickness at end systole(mm)1.38 ± 0.241.41 ± 0.19NS[^2]Table 2Cardiac function in *ex vivo* I/R hearts.Table 2GroupLVDP (mm Hg)LVEDP (mmHg)PP (mmHg)**Baseline** WT88.5 ± 6.25.6 ± 1.972.6 ± 12.1 *Diaph1*^*-/-*^83.1 ± 5.65.2 ± 2.188.1 ± 19.5**I/R** WT31.8 ± 3.928.6 ± 6.696.5 ± 18.6 *Diaph1*^*-/-*^51.2 ± 6.8[⁎](#tf0005){ref-type="table-fn"}7.9 ± 2.9[\#](#tf0010){ref-type="table-fn"}82.7 ± 16.9[^3][^4][^5]

3.3. Diaph1 Deletion Affects F:G Actin Ratio but Minimally Impacts RhoA/Rac1-regulated Signaling {#s0065}
------------------------------------------------------------------------------------------------

Since formins modulate Rho-GTPase signal transduction ([@bb0130]) and regulate actin polymerization ([@bb0250]), we asked whether DIAPH1 mediates its effects in I/R via these mechanisms. RhoA directly stimulates DIAPH1, leading to direct interaction with profilin and stimulation of actin polymerization. Changes in ratio of filamentous (F) to globular (G) actin, a measure of actin polymerization, have been linked to modulation of signal transduction and transcriptional events in various cell types. Western blots ([Fig. 3](#f0015){ref-type="fig"}a) and phalloidin/DNase I staining method using confocal microscopy ([Fig 3](#f0015){ref-type="fig"}b) was used to investigate if DIAPH1 modulates changes in F:G actin. In the current study, the ratio of F:G actin was reduced in cultured sh*Diaph1* H9C2 cells after H/R compared to shScr cells ([Fig. 3](#f0015){ref-type="fig"}a,b), as well as in *Diaph1*^*--/--*^ mouse hearts after *ex vivo* I/R ([Fig. 3](#f0015){ref-type="fig"}c). However, under normoxic conditions, *Diaph1* silencing does not affect F:G actin (Supplementary Fig. S3). Although previous studies revealed that DIAPH1 mediates vascular injury in smooth muscle cells through alterations in Rho GTPases ([@bb0240]), we found no differences in Rac1 phosphorylation or in the expression of RhoA between sh*Diaph1* and shScr cells after H/R (Supplementary Fig. S4a--b). *Diaph1* deletion had no effect on ROCK2 protein levels in H9C2 cells after H/R (Supplementary Figure S4c) or on GSK3β phosphorylation at Ser9 relative to WT mouse hearts after LAD/reperfusion (Supplementary Fig. S4d). We found no differences in DIAPH2 (also known as mDia2) protein levels between shScr and sh*Diaph1* H9C2 cells after H/R, demonstrating that DIAPH2 is not upregulated to compensate for the absence of DIAPH1 (Supplementary Fig. S4e). Thus, DIAPH1 exerts its effects via mechanisms distinct from Rho-mediated signaling to modulate myocardial I/R injury.Fig. 3*Diaph1* deletion inhibited actin polymerization and SRF activation after H/R. (a) F:G actin ratio was reduced in sh*Diaph1* H9C2 cells after H/R (n = 5/group; \*p \< 0.05 vs. shScr) and (b) representative confocal microscopy images indicating changes in F and G actin in sh*Diaph1* H9C2 cells after H/R. Single field images of 1024 × 1024 pixels were collected to visualize F-actin labelled with Alexa Fluor 647 Phalloidin and G-actin labelled with Alexa Fluor® 594 DNase I, Scale bar: 25 μm, (c) F:G actin ratio was reduced in hearts isolated from *Diaph1*^--/--^ mice compared to WT after *ex vivo* I/R (n = 4--5/group; \*p \< 0.05 vs. WT I/R). (d) mRNA expression of *Srf* (n = 6--8/group) and target genes, *Tagln* and *Fos* (n = 16--17/group; normalized to *Ppia*), was decreased after H/R in sh*Diaph1* cells (\*p \< 0.05 vs. shScr). (e) mRNA expression of *Srf* (n = 6/group) and target genes, *Tagln* and *Fos* (n = 16/group; normalized to *Ppia*), was decreased in hearts isolated from *Diaph1*^--/--^ mice compared to WT after *ex vivo* I/R (n = 4/group; \*p \< 0.05 vs. WT I/R) (f) The effects of pretreatment with LatB and Jas on expression of *Srf* (n = 6/group), *Tagln* (n = 9/group), and *Fos* (n = 9/group) in shScr H9C2 after H/R (\*p \< 0.05 vs. vehicle). (g) Nuclear myocardin/GAPDH was reduced in sh*Diaph1* H9C2 cells after H/R (n = 8/group; \*p \< 0.05 vs. shScr). (h) jasplakinolide (Jas) pretreatment increased LDH release in sh*Diaph1* H9C2 cells after H/R (n = 8/group; \*p \< 0.05 vs. shScr). Unpaired two-tailed *t*-tests (a, c, d, g) and one-way ANOVA (e, f) were used; a p-value \< 0.05 was considered significant.Fig. 3

3.4. DIAPH1 Regulates Actin-mediated Transcriptional Changes After I/R Through Serum Response Factor {#s0070}
----------------------------------------------------------------------------------------------------

These unexpected results led us to consider primary roles for DIAPH1 in the regulation of actin polymerization and the stimulation of serum response factor (SRF)-regulated genes. We investigated mRNA levels of *Srf* and its target genes, *Tagln* (Sm22) and *Fos* (c-Fos) ([@bb0105]), and found that they were reduced in sh*Diaph1* cells relative to shScr cells after H/R ([Fig. 3](#f0015){ref-type="fig"}d). Similar reductions in mRNA levels of *Srf* and its target genes, *Tagln* and *Fos* were observed in *Diaph1*^*--/--*^ mouse hearts after *ex vivo* I/R ([Fig. 3](#f0015){ref-type="fig"}e). Under normoxic conditions, *Diaph1* silencing does not have an effect on the expression of these three genes (Supplementary Fig. S5).

To better understand the relationship between F:G actin changes and downstream SRF-driven transcriptional changes, we used the actin polymerization inhibitor latrunculin B, or the actin filament stabilizer jasplakinolide, 1 h prior to H/R in shScr H9C2 cells. As expected, latrunculin B reduced the ratio of F:G actin, and jasplakinolide significantly increased the F:G actin ratio (Supplementary Fig. S6). Since the transcription factor SRF regulates gene transcription downstream of actin polymerization, mRNA levels of *Srf*, *Fos*, and *Tagln* were measured in latrunculin B- and jasplakinolide-pretreated cells after H/R. Latrunculin B pretreatment reduced mRNA expression of these three genes, while jasplakinolide pretreatment increased mRNA expression in shScr H9C2 cells ([Fig. 3](#f0015){ref-type="fig"}f). Furthermore, the protein levels of myocardin, a coactivator of SRF, were significantly reduced in sh*Diaph1* H9C2 cells subjected to H/R ([Fig. 3](#f0015){ref-type="fig"}g). Treatment of sh*Diaph1* cells with jasplakinolide, known to increase F:G actin, significantly reduced LDH release during H/R ([Fig. 3](#f0015){ref-type="fig"}h). These data indicate that DIAPH1 is linked to SRF-regulated transcriptional changes during H/R, at least in part through mechanisms related to altered actin polymerization.

3.5. Early Growth Response 1 (EGR1) is Regulated Downstream of DIAPH1 in I/R Injury {#s0075}
-----------------------------------------------------------------------------------

EGR1 is a transcription factor that may be regulated by SRF ([@bb0090]) and is increased in cardiac stress, including I/R ([@bb0025]). Nuclear EGR1 protein levels were significantly lower in *Diaph1*^--/--^ mouse hearts after LAD/reperfusion relative to WT hearts ([Fig. 4](#f0020){ref-type="fig"}a) and in the nuclear fraction after H/R in sh*Diaph1* cells relative to shScr cells ([Fig. 4](#f0020){ref-type="fig"}b). ChIP assays revealed an interaction between SRF protein and the promoter region of the *Egr1* gene in WT (but not *Diaph1*^--/--^ hearts) subjected to LAD/reperfusion ([Fig. 4](#f0020){ref-type="fig"}c). These data link DIAPH1 to downstream regulation of SRF and EGR1.Fig. 4*Diaph1* deletion downregulated EGR1 expression. (a) *Diaph1* deletion decreased nuclear EGR1/histone 3 after LAD/reperfusion in mouse hearts (n = 4/group; \*p \< 0.05 vs. WT LAD) and (b) *Diaph1* silencing decreased nuclear EGR/nucleoporin p62 in H9C2 cells after H/R (n = 5/group; \*p \< 0.05 vs. shScr H/R). (c) ChIP studies revealed an interaction between SRF protein and the *Egr1* promoter region in WT but not *Diaph1*^--/--^ hearts following LAD/reperfusion (n = 3/group). Unpaired two-tailed t-tests were used; a p-value \< 0.05 was considered significant.Fig. 4

3.6. Diaph1 Deletion Alters Regulation of Calcium-handling Proteins {#s0080}
-------------------------------------------------------------------

Previous studies have suggested that EGR1 may play a role in the maintenance of calcium levels in the heart ([@bb0140], [@bb0245]). Impaired function of calcium transport proteins is a major mechanism of myocardial injury and poor functional recovery following I/R ([@bb0125]). Because *Diaph1*^--/--^ hearts exhibited significantly greater cardiac functional recovery and reduced injury after I/R, we asked whether these outcomes were linked to altered expression of calcium transporter proteins in cardiomyocytes. The sarcoplasmic reticulum calcium ATPase (SERCA)2a shuttles Ca^2 +^ from the cytosol to the lumen of the sarcoplasmic reticulum. It is a key regulator of intracellular Ca^2 +^ in the cardiomyocyte and is inhibited by dephosphorylated phospholamban (PLN) ([@bb0150]). SERCA2a protein was more abundant in *Diaph1*^--/--^ hearts from mice subjected to LAD/reperfusion relative to WT hearts ([Fig. 5](#f0025){ref-type="fig"}a) and in sh*Diaph1* H9C2 cells relative to shScr cells after H/R ([Fig. 5](#f0025){ref-type="fig"}b). However, under normoxic conditions, *Diaph1* silencing did not impact SERCA2a expression in H9C2 cells (Supplementary Fig. S7a). Furthermore, phosphorylation of PLN at serine 16, which stimulates SERCA2a, was higher in sh*Diaph1* cells than in shScr cells after H/R ([Fig. 5](#f0025){ref-type="fig"}c). Expression of the sodium-calcium exchanger NCX1, which also regulates intracellular Ca^2 +^ by removing Ca^2 +^ from the cell in exchange for Na^+^ under normal physiological conditions ([@bb0160]), was reduced in sh*Diaph1* cells compared with shScr cells ([Fig. 5](#f0025){ref-type="fig"}d). Under normoxic conditions, *Diaph1* silencing did not significantly affect NCX1 expression or intracellular calcium in H9C2 cells (Supplementary Fig. S7b--c). *In vivo,* there was an interaction between SRF and the promoter region of the gene for NCX1, *Slc8a1*, in WT hearts (but not in *Diaph1*^--/--^ hearts) from mice subjected to LAD/reperfusion ([Fig. 5](#f0025){ref-type="fig"}e).Fig. 5*Diaph1* deletion improved calcium dynamics after I/R. (a) SERCA2a/GAPDH protein levels were increased by *Diaph1* deletion in both mouse hearts after LAD/reperfusion (n = 10/group; \*p \< 0.05 vs. WT LAD) and (b) H9C2 cells after H/R (n = 4/group; \*p \< 0.05 vs. shScr H/R). (c) Phosphorylated phospholamban (phospho/totalPLN; n = 3--4/group; \*p \< 0.05 vs. shScr H/R) was increased in sh*Diaph1* H9C2 cells after H/R. (d) NCX1/GAPDH protein expression was lower in sh*Diaph1* H9C2 cells after H/R (n = 3/group; \*p \< 0.05 vs. shScr H/R). (e) ChIP studies performed after LAD/reperfusion revealed an interaction between SRF protein and the promoter region for the NCX1 gene, *Slc8a1*, in WT but not *Diaph1*^-/-^ hearts (n = 3/group). (f) Adenoviral *Egr1* overexpression in shScr and sh*Diaph1* H9C2 cells suppressed the effect of DIAPH1 on SERCA2a/GAPDH protein expression after H/R (n = 12/group; \*p \< 0.05 vs. Ad-mock shScr H/R, \#p \< 0.05 vs. Ad-mock sh*Diaph1* H/R). Unpaired two-tailed *t*-tests (a--d) and a two-way ANOVA (e) were used, a p-value \< 0.05 was considered significant.Fig. 5

Finally, to definitively link EGR1 to changes in intracellular calcium, we adenovirally overexpressed *Egr1* in sh*Diaph1* H9C2 cells subjected to H/R. Unlike mock adenovirus, expression of *Egr1* blocked the protective effect of *Diaph1* deletion on SERCA2a ([Fig. 5](#f0025){ref-type="fig"}f). Taken together, these data demonstrate that DIAPH1 plays a role in calcium homeostasis through complex transcriptional mechanisms involving EGR1 and SRF and downstream regulation of *Slc8a1.*

4. Discussion {#s0085}
=============

In the heart, the formins have been shown to play essential roles in development ([@bb0165]). While *Diaph1*^--/--^ mice do not display a pathological cardiac phenotype under normal physiological conditions, our data point to DIAPH1 as a mediator of I/R injury. *Diaph1* deletion reduced infarct size and improved contractile function in mice following LAD/reperfusion, and *Diaph1* gene silencing in H9C2 cells reduced H/R-induced LDH release via the following mechanisms. First, *Diaph1* deletion suppressed actin polymerization and regulated transcriptional changes in cardiomyocytes, particularly through SRF and myocardin. Second, *Diaph1* deletion led to increased SERCA2a expression, increased phosphorylated PLN, and reduced NCX1, in part via EGR1.

Reduced SERCA2a expression has been observed in heart failure patients ([@bb0205]), and mouse hearts with decreased SERCA2a expression are more susceptible to ischemic injury ([@bb0225]). In our studies, increased SERCA2a expression and reduced infarct size after I/R were consistent with a key role for SERCA2a in the cardioprotection observed in *Diaph1*^--/--^ mouse hearts. Previous studies have shown a major role for EGR1 in regulating SERCA2a protein expression. The expression of *Atp2a2*, the gene for SERCA2a, can be induced by reducing MK2-dependent EGR1 in mouse embryonic fibroblasts ([@bb0185]). In rat neonatal cardiomyocytes, EGR1 binds to the 5' regulatory region of the *Atp2a2* gene ([@bb0010]). Furthermore, *Atp2a2* gene expression is decreased in cardiomyocytes isolated *from Egr1*^--/--^ mice ([@bb0140]). In support of these earlier findings, our study shows for the first time that expression of calcium regulating proteins was mediated in part by DIAPH1 in cardiomyocytes through EGR1.

Interestingly, *Diaph1* deletion reduces intracellular calcium not only by increasing SERCA2a protein levels, but also by decreasing NCX1, which is essential for maintaining calcium homeostasis in the cardiomyocyte ([@bb0030]). Deletion of *Slc8a1*, the gene for NCX1, reduces infarct size and improves functional recovery after myocardial I/R in mice ([@bb0135]). Overexpression of *Slc8a1* during heart failure led to diminished calcium stores in the sarcoplasmic reticulum and to subsequent contractile dysfunction ([@bb0035]). *Diaph1* deletion can both upregulate SERCA2a and downregulate NCX1, thus contributing to maintaining calcium homeostasis and reducing subsequent downstream events leading to I/R injury in the heart.

The effect of *Diaph1* deletion on actin polymerization may be another mechanism for reduced injury. While the effects of actin polymerization on I/R-mediated injury have not been studied in cardiomyocytes, disruptions in cytoskeletal and actin-associated proteins, including desmin and tubulin, are associated with contractile dysfunction, hypertrophy, and subsequent heart failure ([@bb0180], [@bb0065]). Furthermore, I/R injury in endothelial cells contributes to F actin bundling, which can lead to apoptosis ([@bb0060]). Actin polymerization requires ATP, which is depleted during I/R. One previous study showed that a model of ATP depletion in LLC-PK~1~ kidney proximal tubules leads to conversion of G actin to F actin ([@bb0020]). In the current study, we found that the F:G actin ratio was reduced in sh*Diaph1* cells after H/R. Hence, more G actin should be available to interact with myocardin and myocardin-related transcription factors, preventing their translocation to the nucleus and subsequent binding to the serum response element on SRF target genes ([@bb0110]). Indeed, it is suggested that the co-activators of SRF, rather than the SRF itself, determine the pathological outcomes of SRF-related gene transcription ([@bb0110], [@bb0100], [@bb0095]). Consistent with these studies, we observed a reduction in nuclear myocardin protein levels and reduced SRF-related gene transcription in sh*Diaph1* H9C2 cells after H/R.

Formins have not been studied in the context of cardiac I/R injury. Intriguingly, a recent report in Japanese subjects with dilated cardiomyopathy, which is associated with systolic dysfunction, uncovered a missense mutation in the gene encoding another formin family gene, formin homology 2 domain containing 3 (FHOD3). Functionally, the mutant was found to modulate actin filament assembly, highlighting potential links of the formins to cardiac injury ([@bb0015]). In addition, we previously demonstrated key roles for DIAPH1 in vascular injury ([@bb0240]). Endothelial denudation injury to the femoral artery in mice upregulated DIAPH1 expression in vascular smooth muscle, and deletion of *Diaph1* reduced pathological neointimal expansion after injury through alterations in Rac1 activation, AKT/GSK3β phosphorylation, and smooth muscle cell migration ([@bb0240]). We did not observe any changes in Rac1 signaling in H9C2 cells after H/R and GSK-3β phosphorylation in *Diaph1*^--/--^ mice hearts after I/R, thereby highlighting the diverse cell-specific mechanisms by which DIAPH1 contributes to pathological responses to stress. It is noted, however, that further detailed studies using tissue specific *Diaph1* knockout mice are required to determine the role of RhoA-driven signaling in DIAPH1-regulated myocardial I/R injury.

In summary, this work implicates DIAPH1 as a critical regulator mediating cardiac dysfunction during I/R. Through integration of a series of key events, DIAPH1 regulates SRF and EGR1 transcription and consequent regulation of calcium transporters ([Fig. 6](#f0030){ref-type="fig"}). Because deletion of *Diaph1* protected against cardiac I/R injury, blockade of DIAPH1-driven mechanisms may reduce injury and slow progression towards heart failure after myocardial infarction.Fig. 6Proposed mechanism for the role of DIAPH1 in I/R injury. DIAPH1 is upregulated following I/R injury, which leads to an increase in actin polymerization. This allows for stimulation of SRF and myocardin, which results in elevated SRF-regulated gene transcription as well as increased EGR1. SRF also stimulates NCX1 expression. Downstream of EGR1, SERCA2a is reduced. The changes in NCX1 and SERCA2a expression contribute to injury and dysfunction in the myocardium.Fig. 6
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[^1]: Deceased.

[^2]: LVESD: left ventricular end systolic diameter, LVEDD: left ventricular end diastolic diameter, n = 10/group.

[^3]: LVDP: left ventricular developed pressure, LVEDP: left ventricular end diastolic pressure, PP: coronary perfusion pressure. n = 6/group.

[^4]: P \< 0.05 vs WT for LVDP comparison in I/R conditions.

[^5]: P \< 0.05 vs WT for LVEDP comparison in I/R conditions.
